HIV control in Rwanda: Lessons and challenges · DHS 2010 0.5 1.5 2.9 3.9 6.3 6.7 5.7 RAIHIS 2013...
Transcript of HIV control in Rwanda: Lessons and challenges · DHS 2010 0.5 1.5 2.9 3.9 6.3 6.7 5.7 RAIHIS 2013...
HIV control in Rwanda:
Lessons and challenges
Sabin Nsanzimana,MD Institute of HIV disease prevention& control
• Landlocked East Africa nation,
• 26,388Km2:
• ~11.5 M, highest pop.density in Africa: 416 ppl./km2
• Life expectancy at birth m/f (years, 2013): 64/67
• HIV prevalence :3%
Country Profile
A Hilly Terrain a.k.a ‘’A country of a Thousand Hills and
thousand solutions
HIV incidence (2004 to 2014) New infections reduced by 50%.
0
5000
10000
15000
20000
25000
30000
35000
197
5
197
6
197
7
197
8
197
9
198
0
198
1
198
2
198
3
198
4
198
5
198
6
198
7
198
8
198
9
199
0
199
1
199
2
199
3
199
4
199
5
199
6
199
7
199
8
199
9
200
0
200
1
200
2
200
3
200
4
200
5
200
6
200
7
200
8
200
9
201
0
201
1
201
2
201
3
201
4
201
5
201
6
201
7
201
8
201
9
Number of new HIV infections
Total PLHIV deaths*
Annual AIDS deaths
TODAY
HIV Related deaths (2014) 78% decline in overall AIDS related deaths (2004 to 2014)
New HIV infection & AIDS related deaths in Rwanda Source: UNAIDS epi spectrum & RBC annual reports
Few years ago … Saving lives with Free Treatment for HIV Infection and Tuberculosis
Kim JY, Farmer P. N Engl J Med 2006;355:645-647.
Before After
March 2003 September 2003
0
1
2
3
4
5
6
7
8
15-19 20-24 25-29 30-34 35-39 40-44 45-49
DHS 2005 0.5 1.6 2.9 5.2 4.9 6.6 4.6
DHS 2010 0.5 1.5 2.9 3.9 6.3 6.7 5.7
RAIHIS 2013 0.4 1.0 2.1 4.4 5.0 7.2 6.5
PER
CEN
T H
IV P
REV
ALE
NC
E
DHS 2005 DHS 2010
Reduction of
HIV Prevalence
among youth
Peak prevalence RAIHIS 2013
RAIHIS : Rwanda AIDS Indicators and HIV Incidence survey
HIV Prevalence
National Average: 3% Male: 2.3% Female: 3.6%
City of Kigali 7.3%
• Even in Kigali, disparity of
prevalence
• High pockets of HIV prevalence:
FSWs: 51% (BSS2010)
HIV prevalence in Rwanda is 3% , BUT…
Source: Rwanda Demography Health Survey (DHS), 2010
51% Core transmitters (Highest prevalence)
Bridging Population (Moderate prevalence)
General Population (Lowest prevalence)
FSW: HIV Core Transmitters in Rwanda
Source: RBC, HMIS 2015
Patients on ART & Patients tested HIV+
0
10000
20000
30000
40000
50000
60000
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
New HIV positive cases
Year over year reduction
associated with every 10%
increase in ART coverage
results into 6% incidence
reduction
Effect of ART coverage on HIV prevention
Source: S. nsanzimana, E. mills & al. abstract,feb. CROI 2015, Seattle ,USA
New infections ~ 10,000
a
Deaths:~ 5000
c All HIV Infected 210,000
b
Treatment as Prevention (TasP)
Global 90-90-90 Targets & Current Status
*McMahon et al. 2015, estimates for LMIC for intention-to-treat
Rwanda’s Progress Towards 90-90-90
208,497
1 Nsanzimana et al, The Lancet HIV feb 2015 2 Drug Resistance Monitoring in selected sites, 2013 3 HMIS , June 2015
210,000
86%
85%
82%
4%
5%
8%
0
50000
100000
150000
200000
HIV Positive people Diagnosed On ART VL suppressed
(< 40 copies /ml)
# o
f H
IV i
nfe
cte
d p
eop
le
Target coverage in HIV program
Sources: 1TracNET data on current program enrollment
90-90-90 Target of 90% of PLHIV
know their status
Under test and treat
Aim to enroll ~36,000 people on
ART, mainly from current Pre-ART
patients1
WHO recommends to treat all HIV+ What next ?
How much?
Can we afford?
How can we operationalize the new recommendations?
How can we retain patients in care (especially healthy
patients)?
How can we measure the benefits and impact?
Can Rwanda afford Test and Treat ?
What are the benefits?
-
50,000
100,000
150,000
200,000
250,000
2013Guidelines
UniversalTreatment
Patient Numbers in 2020 at 95% coverage
8%
256,522
257,842 5%
Early analysis shows in Rwanda, Test & Treat could bring an additional 8% of patients on treatment, with a 5% increase in funding need
Source: 1 Epi Estimate RBC,2014
ARVs
Lab
personel
Ind costs
Early analysis into Universal Treatment in Rwanda suggests a reduction in the number of PLHIV by 2020
2012 2013 2014 2015 2016 2017 20182019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
-
50
100
150
200
250
300
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57
Tho
usa
nd
s
Epi Estimates of PLHIV under 2013 Guidelines vs Universal Treatment
2013 Guidelines 2013 Guidelines Universal Treatment Universal Treatment
Source: 1 Epi Estimates RBC,2014
By adopting Test and Treat, Rwanda may be able to avert 17,800 more infections than under the 2013 Guidelines
-
500
1,000
1,500
2,000
2,500
-
0.5
1.0
1.5
2.0
2.5
3.0
20
14
20
15
20
16
20
17
20
18
20
19
20
20
20
21
20
22
20
23
20
24
20
25
20
26
20
27
20
28
20
29
20
30
Ad
dit
ion
al In
fect
ion
s av
erte
d
Ad
dit
ion
al C
ost
of
AR
T
Mill
ion
s
Incremental Cost and Impact of Moving from 2013 Guidelines to Universal Treatment
Cost increase Infections averted
Average
additional annual
costs for ARVs
and labs
= $ 1.4 million p.a
Additional Infections Averted by Scaling Up
17,800
SAVING:
1st line ARV costs for
17,800 people
= $3.5 million a year
Challenges remaining Funding reduction to support programs:
~40% of external HIV funding declined in 4 years
mainly from the GF and PEPFAR is a major barrier
to end AIDS
It is possible to see the end of AIDS from Rwanda
-With strategic use of resources
-Simplifications of models of care
- Ending AIDS is no longer dream
“La bataille n ‘est pas encore finie”
Conclusion
Acknowledgements • Eric Remera,
• Jpaul Uwizihiwe,
• J Claude Ntirenganya
• Kirk Catherine
• Mary Dain
• Heiner Bucher
• Edward Mills,
• Sophie Hadder
• Agnes Binagwaho
10/1/2015 Rwanda HIV Continuum Care 21
The courage of our convictions